Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04649359 · ClinicalTrials.gov registry record · Phase 2
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
A Phase 2 study of Multiple Myeloma, sponsored by Pfizer.
- Active
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
- 20
- Study locations
NCT04649359: Active Phase 2 study of Multiple Myeloma, sponsored by Pfizer.
NCT04649359 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 187 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04649359, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Primary Outcome
ORR: % of participants with best overall response of confirmed stringent complete response (sCR), CR, very good partial response (VGPR) or PR per IMWG criteria. sCR: CR \& normal serum free light chain (sFLC) ratio \& absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum \& urine, disappearance of any soft tissue plasmacytoma \& \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum \& u
Conditions Studied
Interventions
- DRUG Elranatamab (PF-06863135)
Study Locations (20)
California
- Beverly Hills Cancer Center - Beverly Hills
- The Regents of the University of California - Irvine
- Ronald Reagan UCLA Medical Center Drug information Center - Los Angeles
- The Regents of the University of California - Los Angeles
- UCLA Hematology/Oncology Clinic - Los Angeles
- UCLA Ronald Reagan Medical Center - Los Angeles
- UC Irvine Health - Chao Family Comprehensive Cancer Center - Orange
Georgia
- Winship Cancer Institute @ Emory University Hospital Midtown - Atlanta
- Emory University Hospital - Atlanta
- Emory University - Atlanta
- Winship Cancer Institute, Emory University - Atlanta
- Blood and Marrow Transplant Group of Georgia - Atlanta
- Emory Saint Joseph's Hospital - Atlanta
- Northside Hospital - Atlanta
Illinois
- Northwestern Medical Group - Chicago
- Northwestern Memorial Hospital - Chicago
- Loyola University Chicago performing research at Loyola University Medical Center - Maywood
- Loyola University Medical Center - Maywood
Florida
- Baptist Hospital of Miami - Miami
Indiana
- Indiana Blood and Marrow Transplantation - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2021-02-02 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT04649359 still lists
NCT04649359 is an interventional study that assigns participants to a tested intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Elranatamab (PF-06863135) is the first listed.
NCT04649359 names 20 study sites across 5 states, led by California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT04649359 about?
NCT04649359 is a clinical study titled "MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb". The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma c...
What is the current status of trial NCT04649359?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2021-02-02. Estimated completion is 2026-12-31.
What conditions does trial NCT04649359 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04649359?
The interventions under investigation include: Elranatamab (PF-06863135) (DRUG).
Who is sponsoring clinical trial NCT04649359?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04649359 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04649359's enrollment target sits among peer trials
187 116th of 438 higher than 323 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06153251 · 187 participants · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI